AB0758 PERSISTENCE AND DRUG SURVIVAL RATES OF THE FIRST-LINE BIOLOGICAL (B) DMARDS IN PATIENTS (PTS) WITH PSORIATIC ARTHRITIS (PSA) FROM THE RUSSIAN PSORIATIC ARTHRITIS REGISTRY (RU-PSART)

Abstract

Background Persistence with bDMARDs has only been studied recently in the last few years. But this information is very relevant for choice of bDMARDs treatment in real-life practice. RU-PsART collected data from 25 rheumatology clinics in the Russian Federation. Objectives: to investigate drug survival and persistence rates, reasons for discontinuation of first-line bDMARDs in PsA pts in clinical practice. Methods 170 (M/F–87/83) PsA pts according to CASPAR criteria, median (Me) age 43 (Min 19 – Max 74) years (yrs.) who were treated with first-line bDMARDs were included in the present analysis. All information concerning the data for starting/withdrawing bDMARDs and reasons for discontinuation were taken at the time of being included to the RU-PsART registry. Pts took the following bDMARDs: adalimumab (ADA) (57pts), infliximab (INF) (40pts), Ustekinumab (UST) (36pts), Etanercept (ETN) (23pts), Golimumab (GOL) (14pts). Drug survival rate was evaluated with Kaplan-Meier cumulative analysis, Me [Min-Max],%, Breslow, Tarone-Ware, Log Rank tests were performed. All p≤0.05, were considered to indicate statistical significance. Results 71 out of 170 pts (41.8%) were treated with mono-bDMARDs and 99 out of 170 pts (58.2%) were treated with a combination with different sDMARDs. Among them aDA/INF/UST/ETN/GOL were used in combination with MTX in 66.7%/72.5%/33.3%/65.2%/35.7% of pts accordingly average (Me) duration of bDMARDs therapy was 13.5[0-74]/39[2-179]/15[0-55]/26[2-49]/19[4-33] months for aDA/INF/UST/ETN/GOL accordingly. 31 out of 170 pts (18.2%) stopped bDMARDs. InF/ADA/ETN/UST/GOL were stopped in 30%/22%/17%/5%/0% of cases accordingly. Among them 4 pts (2.35%) stopped due to inefficacy, 13 pts (7.6%) - due to loss of efficacy, 8 pts (4.7%) - due to adverse events, 6 pts (3.5%) - due to other reasons. No significant differences in drug survival rates were seen between all bDMARDs within two years of therapy. During long-term observations GOL had better persistence among iTNF agents. UST has shown significantly higher cumulative survival and persistence rates compared to aDA (p Conclusion In our real practice PsA pts cohort bDMARDs with different mechanisms of action were well tolerated and effective. During long-term observational periods UST has shown better cumulative survival rates compared to aDA. Disclosure of interests Tatiana Korotaeva Speakers bureau: Novartis, Celgene Corporation, abbVie inc, Biocad, Janssen, Pfizer, UCB, Lilly, Elena Loginova Speakers bureau: Novartis, Celgene Corporation, Biocad, Janssen, abbVie inc, anastasia Koltakova: None declared, ELENA GUBAR: None declared, Yulia Korsakova Speakers bureau: Celgene Corporation, Janssen, Maria Sedunova: None declared, Igor Pristavsky: None declared, Irina Umnova: None declared, Irina Bondareva: None declared, Snezana Kudishina: None declared, Evgeny Nasonov Speakers bureau: Pfizer, inc., MSD, Novartis, abbVie inc., Celgen Corporation, Biocad, Janssen, UCB, inc.